Next Article in Journal
The Relationship between the Second-Generation Antipsychotics Efficacy and the Traditional Chinese Medicine Body Constitutions in Patients with Schizophrenia
Next Article in Special Issue
Cancer as a Chronic Illness in Colombia: A Normative Consensus Approach to Improving Healthcare Services for those Living with and beyond Cancer and Its Treatment
Previous Article in Journal
Out of the Closet, Not Yet Out of the House: Gay Men’s Experiences of Homonegativity and Internalized Homonegativity
Previous Article in Special Issue
Clinical Outcomes of Genotype-Matched Therapy for Recurrent Gynecological Cancers: A Single Institutional Experience

The Role of CDK4 in the Pathogenesis of Pancreatic Cancer

Cancer Research Group, School of Life Sciences, University of Westminster, London W1W 6UW, UK
Department of Life Sciences, University of Bedfordshire, Park Square, Luton LU1 3JU, UK
Author to whom correspondence should be addressed.
Academic Editors: Nur Mohammad Hassan, Rahena Akhter and Paolo Cotogni
Healthcare 2021, 9(11), 1478;
Received: 20 August 2021 / Revised: 26 October 2021 / Accepted: 28 October 2021 / Published: 30 October 2021
(This article belongs to the Special Issue Cancer in Human Health and Healthcare)
Pancreatic cancer (PC) continues to have the lowest overall survival and the lack of effective early diagnosis. Cyclin-dependent kinase 4 (CDK4) plays a fundamental role in the orderly progression of the cell cycle, binding to cyclin D to promote the progression through the G1/2 transition. The inhibition of CDK4/6 has therefore gained substantial interest in the hope of new and effective therapeutics in multiple cancers, such as advanced metastatic breast cancer. While the use of these agents is encouraging, their potential is yet to be fully explored. In this study we used the GLOBOCAN database to understand the most recent epidemiology of PC, Human Protein Atlas and KEGG to highlight the role, prevalence, and significance on patient survival of CDK4 in PC. We found that CDK4 cannot be used as prognostic in PC and no significant differences were observed between CDK4 expression and the patient’s clinical status, though larger studies, especially concerning CDK4 protein expressions, are required for a more thorough understanding. The use of CDK4/6 inhibitors in PC is still in clinical trials. However, due to only modest improvements observed in the use of single-agent therapies, efforts have focused on combinatorial approaches. View Full-Text
Keywords: pancreatic cancer; CDK4; CDK4/6 inhibitor; epidemiology pancreatic cancer; CDK4; CDK4/6 inhibitor; epidemiology
Show Figures

Figure 1

MDPI and ACS Style

Jiggens, E.; Mortoglou, M.; Grant, G.H.; Uysal-Onganer, P. The Role of CDK4 in the Pathogenesis of Pancreatic Cancer. Healthcare 2021, 9, 1478.

AMA Style

Jiggens E, Mortoglou M, Grant GH, Uysal-Onganer P. The Role of CDK4 in the Pathogenesis of Pancreatic Cancer. Healthcare. 2021; 9(11):1478.

Chicago/Turabian Style

Jiggens, Emily, Maria Mortoglou, Guy H. Grant, and Pinar Uysal-Onganer. 2021. "The Role of CDK4 in the Pathogenesis of Pancreatic Cancer" Healthcare 9, no. 11: 1478.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop